We are a clinical stage global biotechnology company developing ophthalmic drugs for chronic eye diseases which are often with few treatment options. Our broad pipeline was developed by in-house scientists with the experience and expertise to identify new targeted mechanisms of action and craft formulations that amenable to topical ocular delivery. Our deep understanding of ophthalmic disease pathogenesis and extensive scientific know-how led us to our lead pipeline candidate, CBT-001 – an investigational eye drop treatment with the potential to slow or stop progression of pterygium, a highly underdiagnosed and undertreated disease with no approved drug therapy.
Arog Pharmaceuticals is a private, clinical-stage biopharmaceutical company that has leveraged its platform of benzimidazole derivatives to develop a robust drug pipeline of orally available, potent, and selective small molecule type I kinase inhibitors. Arog is poised to enroll patients in pivotal, randomized Phase III trials of its lead molecule, crenolanib. In addition to the four clinical trials it has already completed, Arog is also engaged in three ongoing Phase II clinical trials.
Get contact details of over 700M profiles across 60M companies – all with industry-leading accuracy.
Sales Navigator and Recruiter users, try out our Email Finder Extension.
Find business and personal emails and mobile phone numbers with exclusive coverage across niche job titles, industries, and more for unparalleled targeting.
Also available via our Contact Data API.